Drug intelligence / Profile preview

mRNA-2137

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**mRNA-2137** is a nucleoside-modified mRNA-based vaccine candidate developed by Moderna, encoding specific immunodominant regions of the SARS-CoV-2 spike protein, potentially targeting emerging variants such as those in the Omicron lineage. It is delivered via lipid nanoparticles to elicit a targeted immune response, including neutralizing antibodies against COVID-19, with a focus on previously vaccinated individuals at high risk. No public clinical trial data or approval status is available as of current knowledge, distinguishing it from related Moderna candidates like mRNA-1283.

Targets

S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on mRNA-2137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-2137.

Explore the full profile